96 completed, 44 terminated, 19 active not recruiting, 10 recruiting. 187 Phase 1, 84 Phase 2.
Follow Revlimid: new trials by email Literature Review of Revlimid trials Research Report on Revlimid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype Dexamethasone, Bortezomib, LENALIDOMIDE - Multiple Myeloma, Triple Negative Breast Cancer | Phase 1 | Recruiting | Andrew Hantel, MD | 90 | 2026-07-30 | 2026-08-17 |
| Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Biospecimen Collection, Computed Tomography, Lenalidomide - Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 30 | 2024-05-20 | 2026-10-26 |
| Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients. Lenalidomide, Obinutuzumab Injection [Gazyva] - Chronic Lymphocytic Leukaemia (CLL), Small Lymphocytic Lymphoma (SLL) | Phase 1 / Phase 2 | Recruiting | Vitebsk Regional Clinical Cancer Centre | 24 | 2024-05-14 | 2026-08-13 |
| MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Multiple Myeloma | Phase 1 | Active not recruiting | Mayo Clinic | 16 | 2024-04-11 | 2026-08-17 |
| Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma Biopsy, Biospecimen Collection, Bone Marrow Biopsy - Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | City of Hope Medical Center | 50 | 2023-08-10 | 2026-10-26 |
| Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma Maplirpacept, Tafasitamab, Lenalidomide - Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Terminated | Pfizer | 6 | 2023-08-04 | 2025-09-05 |
| A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide IMM0306, Lenalidomide capsule - B-cell Non-Hodgkin's Lymphoma | Phase 1 / Phase 2 | Unknown | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 102 | 2023-05-01 | 2023-05-24 |
| Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Lenalidomide, Ublituximab, Umbralisib - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Phase 1 | Withdrawn | Yazeed Sawalha | 2022-09-30 | 2022-09-30 | |
| Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma Selinexor, Bortezomib, Lenalidomide - Multiple Myeloma | Phase 1 / Phase 2 | Unknown | Xia Zhongjun | 42 | 2022-07-25 | 2024-06-17 |
| Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma Tafasitamab, Lenalidomide - CNS Lymphoma, Primary Central Nervous System Lymphoma | Phase 1 / Phase 2 | Recruiting | James Rubenstein | 35 | 2022-06-08 | 2026-07-14 |
| Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System Obinutuzumab, Prednisone, Lenalidomide - Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS), Aggressive B-cell Lymphoma With Secondary Involvement of the CNS | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 14 | 2022-04-19 | 2026-01-08 |
| Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients Lenalidomide, Luspatercept - Myelodysplastic Syndromes | Phase 1 / Phase 2 | Suspended | Mikkael Sekeres, MD | 50 | 2021-11-09 | 2026-07-17 |
| ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma CD47 Antagonist ALX148, Lenalidomide, Rituximab - Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 47 | 2021-10-13 | 2026-09-18 |
| Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL) Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 30 | 2021-08-31 | 2026-10-29 |
| Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma obinutuzumab, prednisone, Revlimid - Lymphoma, Non-Hodgkin Lymphoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 34 | 2021-07-09 | 2026-06-01 |
| A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma EO2463, lenalidomide, rituximab - Follicular Lymphoma, Marginal Zone Lymphoma | Phase 1 / Phase 2 | Recruiting | Enterome | 80 | 2021-07-05 | 2026-01-30 |
| Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma Belantamab Mafodotin, Daratumumab, Dexamethasone - Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma | Phase 1 | Terminated | Mayo Clinic | 5 | 2021-06-03 | 2025-05-18 |
| Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma Bone Marrow Aspiration and Biopsy, Computed Tomography, Echocardiography Test - Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 47 | 2021-05-24 | 2026-10-19 |
| Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL PD-1 Antibody, Lenalidomide - Non-GCB/ABC Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Huiqiang Huang | 30 | 2021-03-31 | 2021-03-15 |
| Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies Romidepsin, Lenalidomide, CC-486 (5-azacitidine) - Cutaneous T-Cell Lymphoma, Mature T-cell Malignancies | Phase 1 | Completed | National Cancer Institute (NCI) | 26 | 2020-12-17 | 2026-10-14 |
Showing 20 of 187. Sign in to see all of them.
Multiple Myeloma (56) · Leukemia, Lymphocytic, Chronic, B-Cell (28) · Lymphoma, Follicular (21) · Lymphoma, Mantle-Cell (21) · Lymphoma, B-Cell, Marginal Zone (20) · Lymphoma, Large B-Cell, Diffuse (20) · Lymphoma (16) · Lymphoma, Non-Hodgkin (15) · Recurrence (14) · Leukemia, Myeloid, Acute (12) · Myelodysplastic Syndromes (12) · Waldenstrom Macroglobulinemia (11) · Burkitt Lymphoma (10) · Lymphoma, B-Cell (10) · Hodgkin Disease (9)
National Cancer Institute (NCI) (22) · M.D. Anderson Cancer Center (20) · Mayo Clinic (9) · City of Hope Medical Center (7) · Massachusetts General Hospital (5) · Case Comprehensive Cancer Center (4) · University of Nebraska (4) · Arbeitsgemeinschaft medikamentoese Tumortherapie (3) · Celgene (3) · Dana-Farber Cancer Institute (3) · Emory University (3) · Oncotherapeutics (3) · Georgetown University (2) · Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH (2) · Hackensack Meridian Health (2)
United States (151) · Germany (8) · France (7) · Canada (5) · Italy (5) · Spain (4) · Austria (3) · China (3) · Switzerland (3) · Australia (2) · United Kingdom (2) · Belarus (1) · Belgium (1) · Denmark (1) · Finland (1)
James R Berenson, MD (3) · Joseph M Tuscano (3) · Elisabet E. Manasanch, MD (2) · Felicitas Hitz, MD (2) · James Rubenstein, MD, PhD (2) · Jatin J. Shah, MD (2) · Mehrdad Abedi, MD (2) · Noopur Raje, MD (2) · Shaji K. Kumar, M.D. (2) · Sikander Ailawadhi, M.D. (2) · Sonali Smith (2) · Agop Y. Bedikian, MD (1) · Ajay Nooka, MD (1)
PMID 18824593, PMID 19182205, PMID 19965642, PMID 20724537, PMID 21149673, PMID 21596852, PMID 21816833, PMID 22033493, PMID 22517904, PMID 22936658, PMID 23100308, PMID 23242596, PMID 23417027, PMID 23592273, PMID 23756764, PMID 23834234, PMID 24004667, PMID 24562384, PMID 24914044, PMID 25052451, PMID 25082342, PMID 25837499, PMID 26058589, PMID 26284823, PMID 26331432, PMID 26643449, PMID 26687423, PMID 27018242, PMID 27646843, PMID 27697771, PMID 27872060, PMID 28099502, PMID 28483761, PMID 29296805, PMID 29610115, PMID 29802551, PMID 29862437, PMID 29986852, PMID 30068505, PMID 30128502, PMID 30190454, PMID 30501870, PMID 31296423, PMID 31723767, PMID 31937615, PMID 32632956, PMID 32704173, PMID 33357482, PMID 34272304, PMID 34320785
U01CA076576 (5), 2009 (4), P30CA014599 (3), P30CA015083 (3), P30CA016058 (3), P30CA036727 (3), U10CA180821 (3), UM1CA186712 (3), 2015 (2), N01CM00071 (2), N01CM62201 (2), P30CA016672 (2), P30CA093373 (2), UM1CA186644 (2), UM1CA186688 (2)